期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗联合化疗治疗复发难治性弥漫大B细胞淋巴瘤18例 被引量：2

原文传递
导出
摘要 目的 评价利妥昔单抗(商品名:美罗华)联合化疗治疗复发难治性弥漫大B细胞淋巴瘤(DLBCL)的临床效果及患者的不良反应.方法 18例DLBCL患者,均经病理证实为CD+20,均为对原方案耐药或缓解后又复发者,在用利妥昔单抗375 mg/m2,静脉滴注,每周1次,共3～4周为1个疗程,同时联合化疗治疗,方案包括MOAP、DICE、COEP、NP、BCNU+VP16、AA、Mito+DDP等.结果 18例患者经治疗后完全缓解(CR)率为55.56%(10/18),总有效率(OR)为77.78%(14/18).1年无进展生存(PFS)率为66.67%,1年总生存(OS)率为77.78%.结论 利妥昔单抗联合化疗是治疗复发难治性DLBCL的有效方法,其CR率高且患者无明显不良反应.
作者 白敏 张巧花 贺建霞 郑玉萍 王列样 王军 韩维娥 侯淑玲
机构地区 山西医科大学研究生处 山西省肿瘤医院血液内科
出处 《白血病．淋巴瘤》 CAS 2008年第2期-,共2页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 大细胞 弥漫型 抗肿瘤联合治疗方案
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Jermann M,Jost L M,Tavema CH. Rituximab-EPOCH,an effective salvage therapy for relapsed,refractory ortransformed B-cell lymphomas:results of a phase Ⅱ study[J].ANNALS OF ONCOLOGY,2004,(03):511-516.doi:10.1093/annonc/mdh093.
  • 2“难治性非霍奇金淋巴瘤的诊断标准”草稿[J].白血病．淋巴瘤,2007,16(5):349-349. 被引量：6
  • 3张之南.血液病诊断及疗效标准[S]北京:科学出版社,1998228-236349-360385-387396-401.
  • 4达永,张伟京,苏航,陈喜林,仲凯励,余金得,俞受程.利妥昔单抗联合化疗治疗CD_(20)^+的B细胞型非霍奇金淋巴瘤27例[J].白血病．淋巴瘤,2006,15(5):371-372. 被引量：9
  • 5白颖,翟明.美罗华联合CEOP方案治疗复发性非霍奇金淋巴瘤疗效观察[J].白血病．淋巴瘤,2003,12(4):215-217. 被引量：4
  • 6Coiffier B,Hiaoun C,Ketterer N. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase Ⅱ study[J].Blood,1998,(06):1927-1932.
  • 7Igarashi T,Itoh K,Kobayashi Y. Phase Ⅱ and pharmacokinetics study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hedgkinps lymphoma[J].Proceedings of the American Society of Clinical Oncology,2002.286a.
  • 8Girouard C,Dufresne J,Imrie K. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hedgkin^s lymphoma prior to autologous bone marrow transplantation[J].Annals of Oncology,1997,(07):675-680.doi:10.1023/A:1008294725992.
  • 9李宇红,姜文奇,黄慧强,张力,刘冬耕,徐瑞华,周中梅,孙晓非,林桐榆,徐光川,何友兼,管忠震.DHAP方案治疗复发和难治性中、高度恶性非霍奇金淋巴瘤的初步观察[J].癌症,2002,21(8):900-902. 被引量：21
  • 10Velasquez WS,MeLaughlin P,Turker S. ESHAP-an effective chemotherapy regiment in refractory and relapsing lymphoma:a 4-year follow-up study[J].Clinical Oncology,1997,(06):1169-1176.

二级参考文献27

  • 1Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro:CD55 and CD59 regulate complement-mediated cell lysis[J]. Blood, 2000,95: 3900-- 3908.
  • 2Maleney D G,Liles T M ,Czerwinski D K,et al. Phase 1 clinical trial using escalating sing-dose infusion of chimeric anti-CD20 monoclollal antibody(IDED-C2B8) in patients with recurrent B-cell lymphoma[J]. Blood, 1998,84 : 2457-- 2466.
  • 3Shall D, ledbetter J A,press O W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies[J].Blood, 1998,91:1644-- 1652.
  • 4Ghetie M A, Bright H, Vitetta E S. Homodimers but not monomers of Rituxan(chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin[J]. Blood, 2001,97: 1392--1398.
  • 5Vose J M,Link B K,Grossbard M L,a al. Phase I study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated ,aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol,2001,19(2) : 389-- 397.
  • 6Coiffier B,Lepage E,Briere J,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(4) : 235- 242.
  • 7Vose JM,Link BK,Grossbard ML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389 -397.
  • 8Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J].N Engl J Med,2002,346(4):235-242.
  • 9Forer A,Lobuglio AF.History of antibody therapy for nonHodgkin's lymphoma[J].Semin Oncol,2003,30 (6 Suppl 17):1-5.
  • 10Demidem A,Lam T,Alas S,et al.Chimeric anti-CD20 (IDECC2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J].Cancer Biother Radiopharm,1997,12(3):177-186.

共引文献78

同被引文献30

  • 1Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol, 2007, 44: 234-245.
  • 2Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high- dose chemotherapy and autologous stem cell support. N Engl J Med, 2004, 350: 1287-1295.
  • 3Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 1995, 333: 1540-1545.
  • 4Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant, 2002, 29: 303-312.
  • 5Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 1999, 94: 3325-3335.
  • 6Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol, 2004, 15: 504-510.
  • 7Galimberti S, Guerrini F, Morabito F, et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by rituximab. Bone Marrow Transplant, 2003, 32: 57-63.
  • 8Plosker GL, Figgitt DP. Rituximab: a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 2003, 63: 803-843.
  • 9Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs, 1999, 58: 79-88.
  • 10Pfreundschuh M, Tramper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. Lancet Oncol, 2006, 7: 379-391.

引证文献2

二级引证文献9

白血病．淋巴瘤
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部